Larimar Therapeutics
LRMR
57 hedge funds and large institutions have $206M invested in Larimar Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 2 closing their positions.
700% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 2
33% more funds holding
Funds holding: 43 → 57 (+14)
0.98% less ownership
Funds ownership: 92.79% → 91.81% (-0.98%)
32% less capital invested
Capital invested by funds: $305M → $206M (-$99M)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.73M |
| 2 |
Millennium Management
New York
|
+$5.76M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$3.98M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.93M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$18.5M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.81M |
| 3 |
O
OrbiMed
New York
|
-$4.89M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$1.11M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$578K |
LRMR Hedge Fund Activity: Q1 2021 in Review
57 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2021, worth a combined $206M — down 32% from $305M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LRMR positions and 2 closed out — a net gain of 14 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $7.73M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $18.5M sold.
- 57 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2021, up from 43 in Q4 2020.
- Funds reported $206M of Larimar Therapeutics stock for Q1 2021, down 32% quarter-over-quarter.
- 16 funds opened new Larimar Therapeutics positions in Q1 2021 and 2 closed out, a net change of +14 holders.
- The largest Larimar Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $7.73M added.
- The largest Larimar Therapeutics seller in Q1 2021 was Acuta Capital Partners, an estimated $18.5M sold.
Based on aggregated 13F filings for Q1 2021.